Building on Experience and Knowledge

Lumos Pharma is a clinical stage biopharmaceutical company committed to identifying, developing and commercializing life-changing therapies for patients and families living with rare diseases. Lumos strives to work with all stakeholders in the rare disease field from universities to patient organizations because we know that you cannot build a strong foundation and rise to important heights in the rare disease world without innovative science and patients.

Science

We are a skilled, rare disease management and investor team, with long-standing scientific experiences ranging from endocrinology to neurology to inborn errors of metabolism. Our collective team experience ranges from developing novel therapeutics in-house to successful multi-party collaborations with academia and government scientists to advance innovative therapeutics to underserved patients.  We search out the best collaborators to help advance our projects no matter where in the world they are performing their science. We are passionately driven to harness innovative science to benefit the patients and caregivers we work with every day.

Patients

Patients, caregivers, and their advocates have been our rare disease partners, walking alongside us as we work relentlessly to develop investigational therapies to help these individuals. We hold in the highest regard and value their knowledge and experiences and respect our collective partnerships. Each and every day, we remain passionately committed to understanding patient and caregiver needs and how to best address them.

Intuition will tell the thinking mind where to look next -Jonas Salk

MANAGEMENT

Lumos Pharma is led by an experienced management team with longstanding experience in the development and commercialization of therapies in the rare disease space.

Rick Hawkins

President & CEO

Rick Hawkins is Chief Executive Officer of Lumos Pharma. Previously, Mr. Hawkins founded Pharmaco and as Chairman, President and Chief Executive Officer, he managed the growth of that organization to over 700 employees. Pharmaco offered a full range…

READ MORE

David M. Weiner, M.D.

Chief Medical Officer

Dave Weiner is Chief Medical Officer of Lumos Pharma. Dr. Weiner has over 20 years of experience in the discovery and clinical development of novel therapeutics for neurological disease.  He started his career at ACADIA Pharmaceuticals, where, over a ten-year…

READ MORE

John C. McKew, Ph.D.

Chief Scientific Officer

John McKew is Chief Scientific Officer of Lumos Pharma.  Dr. McKew has spent the last 25 years developing novel therapeutics. He has successfully moved therapeutics through pre-clinical and into clinical development in publicly traded biotech, large pharma, government…

READ MORE

Carol A. Dutch, MIEM/MBA

Senior Director, Patient Engagement

Carol A. Dutch is Senior Director, Patient Engagement at Lumos Pharma.  Over the course of her 25-year career, Ms. Dutch has led successful global launches of ultra-rare products (Carbaglu®, Normosang ®, Orfadin ®,Cystagon ®, Cystadane ®, Wilzin ®…

READ MORE

Chris Bemben, MBA, PMP

Director, Business Development

Chris Bemben is Director, Business Development at Lumos Pharma. Mr. Bemben has significant experience in drug discovery and development. He held positions of increasing responsibility as a research scientist at Southwest Research Institute from 2008 to 2015. In…

READ MORE

DEVELOPMENT

Minh-Ha T. Do, Ph.D.

Director of Pre-Clinical Innovation

Minh-Ha Do is Director of Pre-Clinical Innovation at Lumos Pharma.  Dr. Do previously played dual roles as Program Scientific Lead and Associate Director of Physiology at a biotechnology company called aTyr Pharma.  There, she was…

READ MORE

Aleksandra Bruchey, Ph.D.

Senior Project Manager

Alex Bruchey is Senior Project Manager at Lumos Pharma. Dr. Bruchey started her career in neuroscience research over 15 years ago at Vanderbilt University. She earned her doctorate degree from the University of Texas at Austin, where she…

READ MORE

Michael O. Thorner, MB, BS, DSc, FRCP, MACP

Head of Endocrine Sciences

Michael Thorner is Head of Endocrine Sciences of Lumos Pharma. Dr. Thorner most recently was Chair of the Department of Medicine and preceding that was Chief of the Division of Endocrinology and Metabolism and Director…

READ MORE

BOARD OF DIRECTORS

G. Gilbert Cloyd

Chairman

G. Gilbert Cloyd, retired Chief Technology Officer of Procter & Gamble, was born in East Cleveland, Ohio. He attended The Ohio State University and received his Doctor of Veterinary Medicine degree in 1969. Following graduation, he…

READ MORE

Rick Hawkins

President & CEO

Rick Hawkins is Chief Executive Officer of Lumos Pharma. Previously, Mr. Hawkins founded Pharmaco and as Chairman, President and Chief Executive Officer, he managed the growth of that organization to over 700 employees. Pharmaco offered a full range…

READ MORE

Michele Park

Clarus Funds

Michele Park, Ph.D., serves as a Partner at Clarus.  Dr. Park joined Clarus in 2006 with five years of sell-side equity research experience covering the biotechnology sector. From 2002-2005, Dr. Park was a research analyst…

READ MORE

Cameron Wheeler

Deerfield Management

Cameron Wheeler, Ph.D., is a Principal on the Private Transactions team at Deerfield. Cameron joined Deerfield in 2014 and focuses on therapeutics companies. Prior to joining Deerfield, Cameron was at Eleven Biotherapeutics for more than…

READ MORE

Carole Nuechterlein

Roche Venture Fund

Dr. Carole Nuechterlein has headed the Roche Venture Fund since 2001. Prior to her current position, she worked in the pharmaceutical/biotech industry as an attorney for ten years. She joined Roche from SangStat in Fremont…

READ MORE

Ed Mathers

NEA

Mr. Mathers joined NEA as a Partner in August 2008 and is focused on biotechnology and specialty pharmaceuticals investments. He is a director of Liquidia Technologies (NASDAQ:LQDA), Ra Pharmaceuticals (NASDAQ:RARX – Chairman), Rhythm Pharmaceuticals (NASDAQ:RYTM),…

READ MORE

Kevin Lalande

Santé Ventures

Mr. Lalande is a Co-Founder and Managing Director of Santé Ventures, a healthcare and life science venture capital firm founded in 2006 which currently manages $380 million across three funds with 30 portfolio company investments. Over…

READ MORE

Jon S. Saxe

Independent

Mr. Saxe has served as a director of over 25 companies and currently is Chairman of the Board of VistaGen (NASDAQ:VTGN) and a board member Durect Corporation (NASDAQ: DRRX). He also serves on the board of the…

READ MORE

Emmanuel Lacroix

Board Observer

Mr. Lacroix joined UCB Ventures in March 2017, as Senior Director, Venture Investments. He is currently a member of the Board of Syndesi Therapeutics, a UCB spinout company that he helped to launch in early…

READ MORE

Emmett Cunningham

Board Observer

Dr. Cunningham joined Clarus Ventures (www.clarusventures.com) in 2006 with more than 20 years of experience in the biomedical and biopharmaceutical sectors.  He is currently Managing Director at Clarus.  Prior to joining Clarus, Dr. Cunningham was…

READ MORE

Robert Heft

Independent

Dr. Robert Heft served as President, Chief Executive Officer, and member of the Board of Directors of Enobia Pharma Inc. (Montreal, Quebec) from 2005-2012. In February 2012, Dr. Heft sold Enobia to Alexion Pharmaceuticals Inc. for USD 1.1 Billion, the largest-ever sale…

READ MORE

SCIENTIFIC ADVISORY BOARD

Gajja Salomons

Professor of Molecular Biology of Neurometabolic disorders VUMedical Center, Netherlands

READ MORE

Nicola Longo

Chief, Medical Genetics Division, Department of Pediatrics University of Utah

READ MORE

OUR OFFICES

LUMOS PHARMA
4200 Marathon Blvd., Suite 200
Austin, Texas 78756
(512) 215-2630